Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B

• Published in: Hepatology communications Vol. 4; no. 1; pp. 8 - 20
• Main Authors: Lok, Anna S., Zoulim, Fabien, Dusheiko, Geoffrey, Chan, Henry L.Y., Buti, Maria, Ghany, Marc G., Gaggar, Anuj, Yang, Jenny C., Wu, George, Flaherty, John F., Subramanian, G. Mani, Locarnini, Stephen, Marcellin, Patrick
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins 01.01.2020; John Wiley & Sons Inc; John Wiley and Sons Inc; Wolters Kluwer Health/LWW
• Subjects: Antigens; Cancer; Clinical trials; Deoxyribonucleic acid; DNA; Enzymes; Hepatitis; Hepatitis B; Immunoassay; Infections; Interferon; Laboratories; Life Sciences; Liver cancer; Original; Studies; United States > US; Asia; North America; Europe

In patients with chronic hepatitis B (CHB), loss of hepatitis B surface antigen (HBsAg) is considered a functional cure. However, HBsAg loss is uncommon with existing therapies, and predictive factors associated with HBsAg seroreversion are unknown. Using pooled data from three phase 3 clinical tria...